Financials data is unavailable for this security.
View more
Year on year Ryvu Therapeutics SA had net income fall 9.94% from a loss of 83.78m to a larger loss of 92.11m despite a 20.32% increase in revenues from 38.95m to 46.86m. An increase in the selling, general and administrative costs as a percentage of sales from 219.24% to 265.46% was a component in the falling net income despite rising revenues.
Gross margin | 64.77% |
---|---|
Net profit margin | -158.15% |
Operating margin | -175.69% |
Return on assets | -23.04% |
---|---|
Return on equity | -37.68% |
Return on investment | -28.01% |
More ▼
Cash flow in PLNView more
In 2023, cash reserves at Ryvu Therapeutics SA fell by 43.98m. Cash Flow from Financing totalled 240.83m or 513.94% of revenues. In addition the company used 84.55m for operations while cash used for investing totalled 195.54m.
Cash flow per share | -3.69 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 8.88 |
---|---|
Tangible book value per share | 8.57 |
More ▼
Balance sheet in PLNView more
Current ratio | 3.32 |
---|---|
Quick ratio | 3.29 |
Total debt/total equity | 0.4085 |
---|---|
Total debt/total capital | 0.29 |
More ▼